Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
Mayinuer Maitituoheti, Emily Z. Keung, Ming Tang, et al.
Cell Reports (2020) Vol. 33, Iss. 3, pp. 108293-108293
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

The language of chromatin modification in human cancers
Shuai Zhao, C. David Allis, Gang Greg Wang
Nature reviews. Cancer (2021) Vol. 21, Iss. 7, pp. 413-430
Open Access | Times Cited: 297
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 250
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Hunain Alam, Ming Tang, Mayinuer Maitituoheti, et al.
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 599-617.e7
Open Access | Times Cited: 189
Squamous cell lung cancer: Current landscape and future therapeutic options
Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1279-1293
Open Access | Times Cited: 99
Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential
Xuemeng Xu, Peng Qiu, Xianjie Jiang, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 7, pp. 1357-1370
Open Access | Times Cited: 99
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities
Tongxin Ge, Xiang Gu, Renbing Jia, et al.
Cancer Communications (2022) Vol. 42, Iss. 11, pp. 1049-1082
Open Access | Times Cited: 87
Epigenetic regulation in cancer
Minzhi Gu, Bo Ren, Yuan Fang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 18
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Yuanwang Pan, Han Han, Hai Hu, et al.
Cancer Cell (2022) Vol. 41, Iss. 1, pp. 88-105.e8
Open Access | Times Cited: 48
KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions
Hieu T. Van, Guojia Xie, Peng Dong, et al.
Journal of Molecular Biology (2024) Vol. 436, Iss. 7, pp. 168453-168453
Open Access | Times Cited: 11
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Metabolism (2020) Vol. 2, Iss. 12, pp. 1413-1426
Open Access | Times Cited: 67
The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor
Elizabeth A. Coe, Jennifer Y. Tan, Michael Shapiro, et al.
PLoS Genetics (2019) Vol. 15, Iss. 12, pp. e1008501-e1008501
Open Access | Times Cited: 61
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors
Shilpa S. Dhar, Min Gyu Lee
Oncotarget (2021) Vol. 12, Iss. 13, pp. 1296-1308
Open Access | Times Cited: 42
Signaling Pathways That Drive18F-FDG Accumulation in Cancer
Jessica R. Salas, Peter M. Clark
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 5, pp. 659-663
Open Access | Times Cited: 26
KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition
Jing Xu, Ailing Zhong, Shan Zhang, et al.
Advanced Science (2023) Vol. 10, Iss. 19
Open Access | Times Cited: 16
Merkel Cell Polyomavirus‒Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation
Thibault Kervarrec, Silke Appenzeller, M. Samimi, et al.
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 3, pp. 516-527
Open Access | Times Cited: 31
Biological effects and regulation of IGFBP5 in breast cancer
Jürgen Dittmer
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 22
Characterizing crosstalk in epigenetic signaling to understand disease physiology
Joanna K. Lempiäinen, Benjamin A. García
Biochemical Journal (2023) Vol. 480, Iss. 1, pp. 57-85
Open Access | Times Cited: 12
KMT2D: A key emerging epigenetic regulator in head and neck diseases and tumors
Kai Wang, F. Benjamin Zhan, X. Yang, et al.
Life Sciences (2025), pp. 123523-123523
Closed Access
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Jinshou Yang, Feihan Zhou, Xiyuan Luo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS
Shilpa S. Dhar, Calena Brown, Ali A. Rizvi, et al.
Cell Reports (2025) Vol. 44, Iss. 5, pp. 115619-115619
Closed Access
Dimethyl itaconate ameliorates the deficits of goal-directed behavior in Toxoplasma gondii infected mice
Yongshuai Wu, Daxiang Xu, Yan He, et al.
PLoS neglected tropical diseases (2023) Vol. 17, Iss. 5, pp. e0011350-e0011350
Open Access | Times Cited: 9
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment
Zibo Zhao, Yuki Aoi, Cassandra N. Philips, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 52
Open Access | Times Cited: 8
Benign and Intermediate-grade Melanocytic Tumors With BRAF Mutations and Spitzoid Morphology
Jeffrey Zhao, Sarah Benton, Bin Zhang, et al.
The American Journal of Surgical Pathology (2021) Vol. 46, Iss. 4, pp. 476-485
Closed Access | Times Cited: 17
Comparison of mutation landscapes of pretreatment versus recurrent squamous cell carcinoma of the oral cavity: The possible mechanism of resistance to standard treatment
Tongchai Payungwong, Krittaya Angkulkrerkkrai, Amphun Chaiboonchoe, et al.
Cancer Reports (2024) Vol. 7, Iss. 3
Open Access | Times Cited: 2
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations
Alexandra M. Haugh, Robert C. Osorio, R François, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1347-1347
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top